A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution’s experience

BACKGROUND: There is a lack of precision medicine in pancreatic ductal adenocarcinoma (PDA) and related cancers, and outcomes for patients with this diagnosis remain poor despite decades of research investigating this disease. Therefore, it is necessary to explore novel therapeutic options for these...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowder, Cinthya Y., Dhir, Teena, Goetz, Austin B., Thomsett, Henry L., Bender, Joseph, Tatarian, Talar, Madhavan, Subha, Petricoin, Emanuel F., Blais, Edik, Lavu, Harish, Winter, Jordan M., Posey, James, Brody, Jonathan R., Pishvaian, Michael J., Yeo, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498307/
https://www.ncbi.nlm.nih.gov/pubmed/32561076
http://dx.doi.org/10.1016/j.suronc.2020.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498307/
https://www.ncbi.nlm.nih.gov/pubmed/32561076
http://dx.doi.org/10.1016/j.suronc.2020.02.003

Ejemplares similares